Accordingly, the in vivo evidence of sertindole to retard bladder tumor growth and lower tyrosine 705-phosphorylated STAT3 levels within bladder tumors is indispensable to substantiating sertindole’s potential as an option for treating bladder cancer. Here, STAT3 is linked to urinary bladder carcinoma.